Navigation Links
Dr. Barry Katzen to Present CATANIA(TM) Coronary Stent Data in Tel Aviv
Date:12/1/2009

NEWNAN, Ga., Dec. 1 /PRNewswire/ -- CeloNova BioSciences, Inc., a provider of specialty surface treatments for medical devices and of specialty implants, today announced that Barry Katzen, MD, FACR, FACC, FSCAI, founder and medical director of Baptist Cardiac & Vascular Institute in Miami, Florida, will discuss the CATANIA(TM) Stent System with NanoThin Polyzene®-F at the Innovations in Cardiovascular Interventions Conference to be held at the Hotel David InterContinental in Tel Aviv, Israel, which will include new information about the stent's coating, Polyzene®-F, and clinical outcomes in coronary, below-the-knee, and neurovascular applications. "We are deeply honored that Dr. Katzen will present these data at the ICI conference where innovation is recognized and celebrated. We believe the CATANIA(TM) stent is the technological breakthrough that interventional cardiologists have needed to dispense with the problems associated with bare metal and drug-eluting stents," said Thomas A. Gordy, President and chief Executive Officer of CeloNova. "Dr. Katzen is a true pioneer in interventional medicine."

(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b)

(Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-a)

(Photo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080-c)

About CeloNova BioSciences: Headquartered in Newnan, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene®-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment for implanted medical devices. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene®-F. Both products are CE Marked. Embozene(TM) Microspheres have been approved by the FDA for the treatment of hypervascularized tumors and arteriovenous malformations. For more information, please visit www.celonova.com.

About Innovations in Cardiovascular Interventions: The ICI meeting for interventional cardiologists, innovators, and industry will be held December 6-8, in Tel-Aviv, Israel. It is a continuation of the series of interventional cardiology conferences held in Israel since 1995. The upcoming meeting will focus on innovative technology, therapies, and research at various levels of development, with thematic live case presentations to present the impact of these technologies on current and future therapy.

Contact: Theresa Wilson +1-770-502-0304; +1-678-895-6486

SOURCE CeloNova BioSciences, Inc.


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... TOKYO , March 29, 2017  The ... unique Japanese public-private partnership formed to battle infectious ... investments totaling US$23 million* that could help deliver ... host of debilitating conditions. This ... a Phase 3 clinical trial testing a pediatric ...
(Date:3/29/2017)... leader in accelerated orthodontics, OrthoAccel ® Technologies, Inc. ... Manal Ibrahim , Kenji Ojima , Ivan ... microlecture presenters at the AcceleDent ® booth (#3037) ... Session, April 21-25, 2017. Orthodontists and their staff are ... a.m. On the opening morning of AAO exhibitions, Sat., ...
(Date:3/29/2017)... 2017 Transparency Market Research ... an exhaustive study of the U.S. substance abuse treatment ... are functional in this market at present, making ... companies, such as GlaxoSmithKline Plc., Pfizer Inc., Alkermes ... various marketing strategies to increase their visibility, the ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... 30, 2017 , ... This morning, more than 275 medical ... support for an independent Vaccine Safety Commission. Five of the signers of the ... hold a press conference at 9:00 AM Friday, March 31 at the ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based dog ... Protect Law that assists dog owners in creating legally-enforceable pet trusts for their ... the natural next step to protect their new companion. Says Evan Dunbar, CEO of ...
(Date:3/29/2017)... ... 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale price ... the remaining days of March, the price will be only $19.97. The EXOUS Bodygear ... just $10 (regular retail price $19.97). , The special promotional prices are to help ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without ... efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with ...
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
Breaking Medicine News(10 mins):